Show simple item record

dc.contributor.authorGüneş, Hacı Murat
dc.contributor.authorGökdeniz, Tayyar
dc.contributor.authorKızılırmak Yılmaz, Filiz
dc.contributor.authorDemir, Gültekin Günhan
dc.contributor.authorGüler, Ekrem
dc.contributor.authorGüler Babür, Gamze
dc.contributor.authorKaraca, Oğuz
dc.contributor.authorÇakal, Beytullah
dc.contributor.authorOmaygenç, Mehmet Onur
dc.contributor.authorİbişoğlu, Ersin
dc.contributor.authorBoztosun, Bilal
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:58:22Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:58:22Z
dc.date.issued2017en_US
dc.identifier.citationGüneş, H. M., Gökdeniz, T., Kızılırmak Yılmaz, F., Demir, G. G., Güler, E., Güler Babür, G. ... Boztosun, B. (2017). Real-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds. Journal of Interventional Cardiology, 30(3), 189-194. https://dx.doi.org/10.1111/joic.12386en_US
dc.identifier.issn0896-4327
dc.identifier.issn1540-8183
dc.identifier.urihttps://dx.doi.org/10.1111/joic.12386
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3157
dc.descriptionWOS: 000405215800001en_US
dc.descriptionPubMed ID: 28440067en_US
dc.description.abstractObjectives: We aimed to evaluate the peri-procedural success of DESolve bio-resorbable scaffolds (BRSs) and analyzed real-life data about major cardiac events during 1-year follow-up. Background: There is little information about real-life data of DESolve BRS which is a novel stent technology offering various advantages over drug eluting stents and commonly used in daily cardiology practice. Methods: We conducted this single-center and non-randomized cross-sectional study from June 2015 through August 2016 in Medipol University Department of Cardiology and included 117 patients undergoing single or multivessel percutaneous coronary interventions (PCI) with novolimus-eluting BRS devices (152 scaffolds) (Elixir Medical Corporation). Study end points were acute device and procedural success, scaffold thrombosis and major adverse cardiac event (MACE) rates of DESolve BRS. Results: Device success was 96.7% and procedural success was 99.3%. We detected MACE rate as 0.9% while clinical-driven target lesion revascularization was performed in one patient. None of the patients experienced scaffold thrombosis or death. Peri-procedural complications were reported in three patients. Conclusions: High rates of successful scaffold implantations, low rates of peri-procedural complications, and major cardiac events in long-term suggest that DESolve scaffolds can safely and effectively be used in daily intervention practice by particularly experienced operators.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectDesolve BRSen_US
dc.subjectDevice Successen_US
dc.subjectMajor Cardiac Eventsen_US
dc.titleReal-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffoldsen_US
dc.typearticleen_US
dc.relation.ispartofJournal of Interventional Cardiologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalıen_US
dc.authorid0000-0001-5825-8627en_US
dc.authorid0000-0003-1919-3183en_US
dc.authorid0000-0001-9975-5507en_US
dc.authorid0000-0002-4607-5724en_US
dc.authorid0000-0002-4281-0867en_US
dc.authorid0000-0003-0230-6575en_US
dc.authorid0000-0003-2995-8792en_US
dc.authorid0000-0002-4951-6716en_US
dc.identifier.volume30en_US
dc.identifier.issue3en_US
dc.identifier.startpage189en_US
dc.identifier.endpage194en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1111/joic.12386en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ2en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record